Kendall Capital Partners
Overview
Kendall Capital Partners is a Boston-based venture capital firm that makes investments in early-stage companies and businesses across the US. The firm primarily focuses on investing in biotech companies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Rejuvenate Bio | Oct 2026 | Crowdfunding | Co-investor |
| Eyenuk | Oct 2022 | Series A | Co-investor |
| EpiBone | Nov 2024 | Convertible Debt | Lead |
| Blu Wireless Technology | May 2019 | Series B | Co-investor |
| General Fluidics Corporation | Jul 2024 | Series B | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Kendall Capital Partners based?
Kendall Capital Partners is headquartered in Boston, Massachusetts, United States.
When was Kendall Capital Partners founded?
Kendall Capital Partners was founded in 2021.
How many portfolio companies does Kendall Capital Partners have?
Kendall Capital Partners has 7 portfolio companies in Caplight's dataset.
What are some companies in Kendall Capital Partners's portfolio?
Portfolio companies visible on Caplight include Rejuvenate Bio, Eyenuk, EpiBone, Blu Wireless Technology, General Fluidics Corporation.
What was Kendall Capital Partners's most recent investment shown here?
Kendall Capital Partners's most recent investment in this portfolio sample was in Rejuvenate Bio in 2026.
What sectors does Kendall Capital Partners focus on?
Kendall Capital Partners focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Telecommunications & Networking, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure.
What company stages does Kendall Capital Partners focus on?
Kendall Capital Partners typically invests at the MultiStage stage.
What is Kendall Capital Partners's AUM?
Kendall Capital Partners's assets under management are estimated between $0.0 and $50.0M.